It has been found that low doses of VEGF inhibitor (apatinib) could regulate the TME, relieve hypoxia, and increase the number of T cells at the tumor site, thereby enhancing the efficacy of PD-1/PD-L1 inhibitors, while excessive doses do not produce such an effect (140). The gene discussed is PDCD1; the disease is neoplasm.